A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

Exclusion Criteria

• •Has received prior treatment with belzutifan or other HIF2α inhibitors
• •Has received prior treatment with cabozantinib
• •Has had radiation therapy for bone metastases within two weeks of starting study drug
• •Has a history of untreated brain metastases or history of leptomeningeal disease or spinal cord compression
• •Has failed to recover from the reversible effects of prior anticancer therapy
• •Has uncontrolled or poorly controlled hypertension
• •Is receiving anticoagulant therapy
• •Has had any major cardiovascular event within 6 months prior to study drug administration
• •Has any other clinically significant cardiac, respiratory, or other medical or psychiatric condition that might interfere with participation in the trial or interfere with the interpretation of trial results
• •Has had major surgery within 3 months before first study drug administration
• •Has an active infection requiring systemic treatment
• •Is participating in another therapeutic clinical trial